'Ecog ps 0 1' diaporamas de présentation

Maintenance Therapy in Advanced NSCLC: State of the Art or State of Confusion

Maintenance Therapy in Advanced NSCLC: State of the Art or State of Confusion Corey J Langer MD, FACP Director Thoracic Oncology Abramson Cancer Center Professor of Medicine Hematology-Oncology Division University of Pennsylvania Philadelphia, PA 19104 Corey.langer@uphs.upenn.edu.

1.22k views • 107 slides

995 views • 69 slides

Highlites in NSCLC: Combined modality treatment in stage III disease

718 views • 56 slides

Chandra P. Belani MD Professor of Medicine University of Pittsburgh School of Medicine

?????? (NSCLC) ?????????????. Chandra P. Belani MD Professor of Medicine University of Pittsburgh School of Medicine Co-Director, Lung & Thoracic Cancer Program University of Pittsburgh Cancer Institute. 100. 80. 60. ????. 40. 20. 0. Stage I. Stage II. Stage III. Stage IV.

701 views • 49 slides

New Agents in the Treatment of Esophageal and Gastric Cancers

New Agents in the Treatment of Esophageal and Gastric Cancers. Heinz-Josef Lenz, MD Professor of Medicine USC/Norris Comprehensive Cancer Center University of Southern California Keck School of Medicine Los Angeles, CA. Can Gastric Cancer be the next GIST? Intestinal versus Diffuse?.

650 views • 43 slides

David H. Ilson, M.D., Ph.D. GI Oncology Service Memorial Sloan-Kettering Cancer Center

Beyond Trastuzumab: The potential for Lapatinib, Pertuzumab, T-DM1 and combinations in GE Adenocarcinoma. David H. Ilson, M.D., Ph.D. GI Oncology Service Memorial Sloan-Kettering Cancer Center New York, NY. DISCLOSURES. Grant/Research Support Amgen Bayer Bristol-Myers Squibb Consultant

551 views • 36 slides

Maintenance therapy for NSCLC

Maintenance therapy for NSCLC. Istituto Toscano Tumori-Livorno-Italy. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile Livorno-Italy. The maintenance therapy paradigm. No progression after 4 cycles of platinum-based CT, PS=0-1.

543 views • 35 slides

The HER Superfamily of Receptors and Related Pathways in Gastroesophageal Cancers

The HER Superfamily of Receptors and Related Pathways in Gastroesophageal Cancers. AKA: ToGA: The starting point. Jordan Berlin, M.D. Ingram Associate Professor of Medicine Vanderbilt-Ingram Cancer Center. Disclosures. For this talk Advisory board and research support: Roche/Genentech

489 views • 33 slides

Follicular Lymphoma Transformed Lymphoma Diffuse Large B-Cell Lymphoma

Follicular Lymphoma Transformed Lymphoma Diffuse Large B-Cell Lymphoma. John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Professor of Medicine, Weill Cornell Medical College Associate Director, Weill Cornell Cancer Center.

829 views • 30 slides

1-line Treatment of Advanced-NSCLC WT

296 views • 28 slides

Discussant: M Ducreux, MD, PhD Institut Gustave Roussy, Villejuif France

TH-302 plus Gemcitabine vs. Gemcitabine in Patients with Untreated Advanced Pancreatic Adenocarcinoma. MJ Borad, Mayo Clinic, Scottsdale, AZ et al. Discussant: M Ducreux, MD, PhD Institut Gustave Roussy, Villejuif France. New drug, new concept, microenvironment.

325 views • 20 slides

306 views • 17 slides